816 related articles for article (PubMed ID: 28181854)
1. Effects of Coexistent BRAF
Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
[TBL] [Abstract][Full Text] [Related]
2. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
3. A six-genotype genetic prognostic model for papillary thyroid cancer.
Shen X; Liu R; Xing M
Endocr Relat Cancer; 2017 Jan; 24(1):41-52. PubMed ID: 27875244
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
5. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
[TBL] [Abstract][Full Text] [Related]
6. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Xing M; Liu R; Liu X; Murugan AK; Zhu G; Zeiger MA; Pai S; Bishop J
J Clin Oncol; 2014 Sep; 32(25):2718-26. PubMed ID: 25024077
[TBL] [Abstract][Full Text] [Related]
8. [
Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125
[TBL] [Abstract][Full Text] [Related]
9. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
[TBL] [Abstract][Full Text] [Related]
10. TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.
Myung JK; Kwak BK; Lim JA; Lee MC; Kim MJ
Cancer Res Treat; 2016 Jul; 48(3):942-7. PubMed ID: 26727717
[TBL] [Abstract][Full Text] [Related]
11. The Genetic Duet of
Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
[No Abstract] [Full Text] [Related]
12. TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis.
Liu C; Liu Z; Chen T; Zeng W; Guo Y; Huang T
Sci Rep; 2016 Nov; 6():36990. PubMed ID: 27833153
[TBL] [Abstract][Full Text] [Related]
13. Frequent BRAF
Oishi N; Kondo T; Nakazawa T; Mochizuki K; Inoue T; Kasai K; Tahara I; Yabuta T; Hirokawa M; Miyauchi A; Katoh R
Endocr Pathol; 2017 Jun; 28(2):103-111. PubMed ID: 28176151
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis.
Vuong HG; Altibi AMA; Duong UNP; Hassell L
Clin Endocrinol (Oxf); 2017 Nov; 87(5):411-417. PubMed ID: 28666074
[TBL] [Abstract][Full Text] [Related]
15. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.
Vuong HG; Altibi AM; Duong UN; Ngo HT; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T
Tumour Biol; 2017 Oct; 39(10):1010428317713913. PubMed ID: 29037127
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.
Sun J; Zhang J; Lu J; Gao J; Ren X; Teng L; Duan H; Lin Y; Li X; Zhang B; Liang Z
PLoS One; 2016; 11(4):e0153319. PubMed ID: 27064992
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors.
Matsuse M; Yabuta T; Saenko V; Hirokawa M; Nishihara E; Suzuki K; Yamashita S; Miyauchi A; Mitsutake N
Sci Rep; 2017 Feb; 7():41752. PubMed ID: 28150740
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
[TBL] [Abstract][Full Text] [Related]
19. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
20. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
